The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 14:21

HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.

HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.

Zhitong FinanceDec 13 07:20

Consun Pharma Passes Key Governance Resolution

TipRanksDec 12 16:40

Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities

BreakingsDec 12 07:38

Express News | The tenth batch of national centralized procurement will open bids in Shanghai tomorrow: involving 62 varieties, with strict measures to prevent companies from colluding and manipulating the bidding.

BreakingsDec 11 17:13